Neuromacin
Macin-family antimicrobial protein with reported neuronal-tissue specificity — leech innate immunity component.
- Hementerin80 kDa
- Hementin80 kDa
- Hementin-Like Protein (HLP-1)80 kDa
- Leech Collagenase70 kDa
- Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
- Leech Apyrase67 kDa
- Calin65 kDa
- Hyaluronidase60 kDa
- Antithrombin III binding protein58 kDa
- Collagenolytic Fibrinolysin55 kDa
- Leech Thrombospondin-Like Protein50 kDa
- Neuromacin6.5 kDa
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- In vitro
- Drug vs leech
- Purified natural compound
- Safety domains
- Aeromonas infection
Clinical translation limit
Neuromacin's in vitro antimicrobial activity does NOT establish clinical efficacy. No FDA-approved derivative exists. The macin family remains a preclinical innate-immunity research target.
Molecular Profile
- Category
- Antimicrobial
- Evidence tier
- Preclinical
- Molecular weight
- 6,500 Da
- Source species
- Hirudo medicinalis
- Discovered
- 2008
Biological Targets
- → bacterial membranes (Gram-positive emphasis)
Key Citations
- Jung S et al. (2012), J Biol Chem · PMID 22396551
External Resources
Related Antimicrobial Compounds
Theromacin
Cationic, cysteine-rich antimicrobial peptide (75 amino acids) active against Gram-positive bacteria — part of the leech's innate immunity.
Theromyzin
Linear anionic antimicrobial peptide (86 amino acids) active against Gram-positive bacteria — the first anionic antimicrobial peptide described in invertebrates.
Macrostomin
Antimicrobial peptide active against Gram-positive bacteria — amphipathic alpha-helix.
Hirunipins
Newly-characterized antimicrobial peptide family (Kumar 2025) — candidate next-generation antibiotics against AMR pathogens.